Ruxolitinib Combination Therapy
Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Ruxolitinib, Methylprednisolone and Lenalidomide: Using Changes in Serum B-Cell Maturation Antigen (BCMA) or International Multiple Working Group (IMWG) Criteria to Determine Disease Progression in Order to Add Lenalidomide to Those Failing the Ruxolitinib/Methylprednisolone Combination
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 30 patients (estimated)
- Sponsors
- Oncotherapeutics
- Collaborators
- Incyte Corporation
- Tags
- JAK1 Inhibitor, JAK2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2029
- NCT Identifier
- NCT06209606
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.